Phase 3 Lymphoma Trial, Recruiting NCT07168980 Sponsor: Children's Cancer Group, China Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT07168980
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of mature B-cell blood cancer (such as Burkitt lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMLBL), or a similar aggressive B-cell cancer), confirmed through a tissue or cell sample test
  • People who are able to attend scheduled follow-up appointments and manage any side effects as required by the trial
  • People who have signed a form giving their informed consent to participate

Who may not be able to join:

  • People diagnosed with follicular lymphoma, MALT lymphoma, or nodular marginal zone lymphoma, as these types are not included in this study
  • People who have a condition where the immune system does not work properly from birth, a chromosomal fragility disorder, a history of organ transplant, any previous cancer of any kind, or a known positive HIV test result
  • People who are pregnant, breastfeeding, or who have received any previous cancer treatment (except corticosteroids taken for less than one week)
  • People whose cancer cells do not carry a protein called CD20 on their surface
  • People who have previously been treated with a medicine called rituximab
  • People who are carriers of Hepatitis B, have a history of Hepatitis B virus infection, or have a positive Hepatitis B blood test result

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yi-jin Gao, Shanghai Children's Medical Center

Phone: +82064 86-21-38626161

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Children's Cancer Group, China
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Event free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov